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Abstract
The generation of kinins on the surface of vascular endothelium has been postulated in two pathways involving plasma kallikrein and
tissue kallikrein; the former pathway has been well documented, but the latter is controversial. To clarify the presence of a kinin-generating
system on endothelium, we examined whether human umbilical vein endothelial cells (HUVEC) synthesize and release tissue kallikrein in
vitro. Kallikrein-like activity hydrolyzing a peptide Pro-Phe-Arg-4-methyl-coumaryl-7-amide was detected in the culture medium of HUVEC
and was inhibited by aprotinin but not by soybean trypsin inhibitor. Western blotting of HUVEC medium using anti-human tissue kallikrein
antibodies demonstrated the release of tissue kallikrein from HUVEC, and the reverse transcription-polymerase chain reaction (RT-PCR)
followed by Southern blotting revealed the expression of tissue kallikrein mRNA in HUVEC. HUVEC metabolically labeled with
[35S]methionine released radioactive proteins corresponding to tissue kallikrein. RT-PCR also showed the expression of low-molecular-
weight kininogen (L-kininogen) mRNA in HUVEC. The cGMP levels in HUVEC were significantly elevated by the incubation with
angiotensin converting enzyme inhibitor, lisinopril, and the elevation was completely inhibited by aprotinin or bradykinin B2-receptor
antagonist, FR172357. These results suggest that the endothelial cells continuously release an active form of tissue kallikrein which enables
generation of kinins on the vascular endothelium.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The vascular tissue has been identified to be a paracrine
and autocrine organ regulating blood flow by various vaso-
active factors. Kinins, such as bradykinin and kallidin,
generated in plasma mainly act on endothelial cells via B2-
receptor to release various agents associated with vascular
tonus and blood coagulation, such as prostaglandins, nitric
oxide (NO), cytokines, and tissue plasminogen activator,
resulting in the maintenance of circulation homeostasis [1].
Kinins are generated in the circulation by at least two
different routes involving plasma kallikrein and tissue kal-
likrein, respectively. Plasma kallikrein (EC 3.4.21.34),
which is activated from the circulating zymogen, prekallik-
rein, on the surface of endothelial cells during the initiation
of intrinsic coagulation then cleaves high-molecular-weight
kininogen (H-kininogen) to liberate bradykinin [2,3]. On the
other hand, tissue kallikrein (EC 3.4.21.35) is a serine
protease (hK1) encoded by one of the kallikrein gene family
consisting of at least 15 genes (KLK1–KLK15) in humans
[4]. Tissue kallikrein is distinct from plasma kallikrein in the
origins of synthesis and the physicochemical properties, such
as molecular size, substrate specificity, and the susceptibility
to various inhibitors [1]. Tisssue kallikrein cleaves L- and H-
kininogens to liberate Lys-bradykinin which is rapidly con-
verted to bradykinin by aminopeptidases in plasma [1].
Low levels of tissue kallikrein have been detected in
plasma [5]. Since the major sources of tissue kallikrein are
exocrine glands such as the kidney, pancreas, and salivary
gland, the origin of tissue kallikrein detected in plasma was
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suggested to be these organs and tissues [6]. However,
several findings have suggested that the tissue kallikrein–
kinin system is present within the vascular wall; a kallikrein-
like kininogenase activity is present in and released from
vascular tissue [7,8], and the expressions of mRNAs for
tissue kallikrein and kininogens were also demonstrated in
vascular tissues [9]. Furthermore, the immunoreactivity of
tissue kallikrein was detected in human endothelial cells
[10,11], and the endothelial and smooth muscle cells in
human blood vessels were demonstrated to be the sites of
synthesis of tissue kallikrein by means of in situ hybrid-
ization [11]. Recently, Dedio et al. [12] reported that human
umbilical vein endothelial cells (HUVEC) synthesized and
stored tissue kallikrein with molecular sizes of about 50 kDa
recognized by anti-tissue kallikrein antibodies, suggesting
that the endothelial cells are a source of tissue kallikrein in
the vascular wall. However, evidence that tissue kallikrein
synthesized by HUVEC is released from the endothelial
cells as an active form of the enzyme has not been provided.
In the present study, we demonstrated that HUVEC synthe-
size and release an active form of tissue kallikrein with a
molecular size of about 30 kDa, and therefore suggest that
there is a tissue kallikrein-dependent kinin generation on the
surface of endothelial cells, which probably plays important
roles in the maintenance of circulation homeostasis.
2. Materials and methods
2.1. Materials
HUVEC, human coronary artery endothelial cells
(HAEC), human coronary artery smooth muscle cells
(HSMC), endothelial basal medium (EBM), and endothelial
cell growth supplement were purchased from Clonetics;
HeLa cells from Human Science Research Resources Bank
(Osaka, Japan); fetal calf serum (FCS) from Invitrogen;
rabbit anti-human tissue kallikrein from Calbiochem; His-
tofine SAB-PO Kit from Nichirei Co. (Tokyo, Japan);
aprotinin, aprotinin-agarose, soybean trypsin inhibitor, and
3-isobutyl-1-methyl-xanthine (IBMX) from Sigma; Pro-
Phe-Arg-4-methyl-coumaryl-7-amide (Pro-Phe-Arg-MCA)
and 7-amino-4-methylcoumarin (AMC) from Peptide Insti-
tute, Inc. (Osaka, Japan). Tissue kallikrein purified from
human urine was supplied by Japan Chemical Research Co.
(Kobe, Japan). FR172357, a specific B2-receptor antago-
nist, and lisinopril were supplied by Fujisawa Pharmaceut-
ical Co. (Osaka, Japan) and Shionogi & Co. (Osaka, Japan),
respectively.
2.2. Cell cultures
HUVEC and HAEC were cultured in EBM supplemented
with endothelial cell growth supplement and 10% FCS. After
four to six passages of cultures, cells were seeded into 75-
cm2 dishes and used for experiments at confluence.
2.3. Assay of tissue kallikrein-like enzyme activity in the
HUVEC-conditioned medium
The tissue kallikrein-like enzyme activity was assayed
using the synthetic peptide Pro-Phe-Arg-MCA as the sub-
strate [13]. HUVEC in 75-cm2 dishes were washed twice
with Ca2+, Mg2+-free Hank’s balanced salt solution (HBSS),
then cultured in EBM. The conditioned medium (about 7
ml) was dialyzed overnight against distilled water at 4 jC,
then the dialyzate was lyophilized. The lyophilizate was
dissolved in 0.5 ml of 0.1 M Tris–HCl, pH 7.8, containing
10 Ag/ml of bovine serum albumin and 0.1 M NaCl (Buffer
1). The sample (50–100 Al) was mixed with Buffer 1 in a
total volume of 0.5 ml and incubated for 5 min at 37 jC
with or without 20 Ag of aprotinin. Ten microliters of 5 mM
Pro-Phe-Arg-MCA dissolved in dimethylsulfoxide was
added, then the mixture was further incubated for 1 h.
Reaction was terminated by adding 2 ml of 12% acetic
acid, and the liberated AMC was determined using a
spectrofluorometer (Hitachi F3000) at 380 nm (exitation)
and 460 nm (emission) using AMC as a standard. The
sample incubated in the presence of aprotinin was used as a
blank. Enzyme activity was expressed as nmol AMC/mg
protein of HUVEC/h. Cell protein levels were measured
using the BCA Protein Assay Reagent (Pierce).
2.4. Western blots of human tissue kallikrein
Conditioned medium (500 ml) of HUVEC was harvested,
then applied to a column of aprotinin–agarose (1.52.0 cm)
equilibrated with 50 mM Tris–HCl, pH 8.0, containing 0.5
M NaCl. The column was washed with 20 ml of the
equilibrium buffer, and the adsorbed proteins were eluted
with 0.1 M glycine–HCl, pH 2.5. The eluate was neutralized
immediately with 1 M Tris–HCl, pH 8.5. Fractions contain-
ing kallikrein-like activity on the synthetic peptide Pro-Phe-
Arg-MCA were pooled, dialyzed against distilled water at 4
jC, then lyophilized. The lyophilizate was resolved by
sodium dodecylsulfate polyacrylamide gel electrophoresis
(SDS-PAGE) in a 10% gel, then electrophoretically trans-
ferred to Immobilon-PSQ membrane (Millipore). The mem-
brane was then blocked with 10% skimmed milk followed by
incubation with rabbit anti-human kallikrein antibody. Rab-
bit IgG on the membrane was detected by the avidin–
biotin–peroxidase complex method according to the instruc-
tion manual issued by Bio-Rad Laboratories.
2.5. Reverse transcription-polymerase chain reaction (RT-
PCR) Southern blot analysis of tissue kallikrein and low-
molecular-weight kininogen (L-kininogen) mRNAs in
HUVEC
Expressions of tissue kallikrein and L-kininogen mRNAs
in endothelial cells were determined by RT-PCR followed
by Southern blotting using an oligonucleotide probe (5V-
ACTTGTTTGACGACGAAAAC-3V) for tissue kallikrein or
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human L-kininogen cDNA for L-kininogen, as follows.
Total RNA was extracted with acid guanidinium–phenol–
chloroform from HUVEC, HSMC, and HeLa cells for tissue
kallikrein or HUVEC, HAEC, and HepG2 cells for kini-
nogen. Total RNA (0.5 Ag) was reverse-transcribed in a 20-
Al reaction mixture containing 50 pmol of the reverse
primer, 2 Al of 10 mM dNTP, 2 Al of 10 PCR buffer
(0.1 M Tris–HCl, pH 8.3, 500 mM KCl), 4 Al of 25 mM
MgCl2, 1 unit of RNase inhibitor, and 1 unit of cloned
Moloney murine leukemia virus reverse transcriptase (Invi-
trogen). The RT reaction mixture was incubated at 42 jC
for 15 min, 95 jC for 5 min, then 5 jC for 5 min to allow
synthesis of the first strand of cDNA. The cDNA was
amplified in a 100-Al reaction mixture containing 50 pmol
of the forward primer, 8 Al of 10PCR buffer, 4 Al of 25
mM MgCl2, and 2.5 units of Taq DNA polymerase. Forty
cycles proceeded as follows: denaturation at 95 jC for 1
min, annealing at 55 jC for 2 min, and extension at 72 jC
for 3 min. RT-PCR products (8 Al) were Southern blotted
and autoradiographed using a Fuji Film Bio Imaging
Analyzer BAS1000 (Fuji Film, Tokyo). The forward and
reverse primers for tissue kallikrein, L-kininogen, or H-
kininogen were 5V-TGGGTGCTCACAGCTGCTCA-3V
(exon 2) and 5V-TTCTCCAGGAGGCTCATGTT-3V (exon
3) [14], 5V-CAGACTGCAAGTCCCTTTGG-3V (exon 5)
and 5V-TCAAGAGACCTCCCTCTCAG-3V (exon 11), or
5V-GCATACATCGATATTCAGCTACGAA-3V(exon 7) and
5V-TGAATCCCGCTCTTCATCTTGTGCA-3V (exon 10),
respectively.
2.6. Radiolabeling of HUVEC and HAEC cultures and
immunoprecipitations with anti-human tissue kallikrein
antibodies
HUVEC and HAEC were grown to confluency in 75-cm2
dishes and washed three times with methionine-deficient
MEM. Methionine-deficient MEM supplemented with
[35S]methionine (3.7 MBq/m1) was added to the cultures,
then cells were incubated for 24 h. The medium was
harvested and centrifuged at 8000g. The supernatant was
mixed with an equal volume of 20 mM Tris–HCl buffer
(pH 7.4) containing 0.28 M NaC1, 5 mM EDTA, 1% Triton
X-100, 0.2 mM phenylmethylsulfonyl fluoride, 2 pg/ml of
leupeptin, and 0.2% bovine serum albumin. The sample (5
ml) was mixed with 0.5 ml of immunoprecipitation buffer
(I-buffer, 10 mM Tris–HC1 (pH 7.4) containing 2.5 mM
EDTA, 0.14 M NaCl and 0.5% Triton X-100), and 0.5 Al of
rabbit anti-human tissue kallikrein serum. In some immu-
noprecipitation tubes, 200 ng of human urinary kallikrein
was added to compete with radiolabeled tissue kallikrein for
antibody binding. After incubation at 4 jC for 18 h, 200 Al
of a 20% suspension of Protein A-agarose was added,
mixed, and incubated for 2 h at 25 jC. The gel was washed
five times with I-buffer, resuspended in 200 Al of 0.125 M
Tris–HC1 (pH 6.8) containing 4% SDS, 10% 2-mercaptoe-
thano1, 20% glycerol, and 0.2% bromophenol blue, then
heated in boiling water for 2 min. The supernatant (20 Al)
was loaded onto a 10% polyacrylamide gel containing 0.1%
SDS and resolved by electrophoresis. The gel was then
fluorographed using sodium salicylate [15], then dried and
autoradiographed using a Fuji Film Bio Imaging Analyzer
BAS2000 (Fuji Film). Similar procedures of radiolabeling
and immunoprecipitations with anti-human tissue kallikrein
antibodies were carried out in HeLa cells as a positive
control.
2.7. Immunostaining of tissue kallikrein in HUVEC using
anti-human tissue kallikrein antibodies
HUVEC were cultured in glass disks coated with Cell-
matrix type I-A (Nitta Gelatin Co., Japan). Cells were
treated with paraformaldehyde and dehydrated using meth-
anol, then immunostained with rabbit anti-human tissue
kallikrein antibodies at dilution of 1:1000. Cells were
incubated with a secondary biotinylated goat anti-rabbit
IgG, then color development was performed by an immu-
noperoxidase staining procedure (Histofine SAB-PO Kit;
Nichirei) using AEC substrate (Nichirei).
2.8. Measurement of cGMP levels in HUVEC after the
addition of lisinopril
HUVEC were seeded in collagen type 1-coated plates (4
cm2) and cultured until confluence in EBM supplemented
with endothelial cell growth supplement and 10% FCS. The
cells were washed with 2-ml HBSS twice, then incubated in
1-ml HBSS containing 0.1 mM IBMX at 37 jC for 15 min.
Cells were incubated for 30 min with or without lisinopril (1
AM), FR172357 (1 AM ), or aprotinin (10 Ag/ml) at 37 jC.
The reaction was terminated by aspirating HBSS followed
by the addition of 0.1 N HCl (500 Al). The cell suspensions
were snap-frozen and stored at 80 jC until assay. The cell
suspensions were centrifuged, and cGMP measured from
neutralized supernatant using cGMP RIA kits (Amersham,
Buckinghamshire, UK).
3. Results
3.1. Kallikrein-like enzyme activity in the HUVEC-condi-
tioned medium
We used a synthetic peptide Pro-Phe-Arg-MCA to detect
tissue kallikrein activity in HUVEC culture medium.
Although Pro-Phe-Arg-MCA is a relatively specific sub-
strate for tissue kallikrein [13], the culture medium of
HUVEC appeared to contain various proteases or peptidases
hydrolyzing this peptide. Therefore, to estimate the tissue
kallikrein-dependent hydrolyzing activity in the conditioned
medium of HUVEC, we determined the aprotinin-suscep-
tible hydrolysis of this susbstrate as a kallikrein-like activity.
Since the kallikrein-like activity in conditioned medium was
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very low, we concentrated the conditioned medium about
20-fold by lyophilization before the assay and found that
greater than 80% of the hydrolyzing activity was inhibited
by aprotinin (40 Ag/ml). As shown in Fig. 1, the kallikrein-
like activity was increased in the course of culture, suggest-
ing that the hydrolyzing enzyme(s) is secreted from
HUVEC. This enzyme activity was inhibited by serine
protease inhibitors, such as phenylmethylsulfonylfluoride
and benzamidine, but not by soybean trypsin inhibitor, a
potent inhibitor for plasma kallikrein (data not shown). We
could not detect a tissue kallikrein-like activity in lysates of
HUVEC because greater than 90% of the hydrolyzing
activity in lysates was not inhibited by aprotinin, probably
due to the nonspecific hydrolysis by various proteases.
3.2. Presence of immunoreactive tissue kallikrein in
HUVEC and their conditioned medium
To demonstrate the presence of tissue kallikrein in the
culture medium of human endothelial cells, the kallikrein-
like enzyme in the conditioned medium of HUVEC was
concentrated by an aprotinin – agarose column, then
resolved by Western blotting using a polyclonal antibody
for human tissue kallikrein. As shown in Fig. 2, Western
blotting using rabbit anti-human tissue kallikrein antibodies
demonstrated that the conditioned medium contained a
single broad immunoreactive band with an apparent molec-
ular size of about 30 kDa that was indistinguishable from
human urinary kallikrein. Culture medium alone before
seeding cells showed no immunoreactive material for anti-
human tissue kallikrein.
Fig. 3 illustrates the immunohistochemical staining of
tissue kallikrein in HUVEC; the intensive immunoreac-
tivity was seen in granules localized near the cell mem-
branes.
3.3. Demonstration of mRNA expression of tissue kallikrein
and L-kininogen in HUVEC
To clarify whether HUVEC express tissue kallikrein
mRNA, RNA extracted from HUVEC was reverse-tran-
scribed and amplified to the corresponding cDNA using
primers specific for human tissue kallikrein cDNA [14]. The
representative Southern hybridization demonstrated an
amplified 155-bp fragment of tissue kallikrein cDNA from
HUVEC RNA (Fig. 4). A similar amplification was also
observed in the RNA sample from smooth muscle cells of
human coronary artery or HeLa cells which was reported to
express tissue kallikrein [11,14].
To determine whether HUVEC express kininogen
mRNA, total RNA samples from HUVEC or HAEC were
examined by RT-PCR followed by Southern blotting using
primers specific for L-kininogen cDNA and H-kininogen
cDNA. A clear signal was detected corresponding to the
amplified product of 638 bp from L-kininogen mRNA in
Fig. 1. Kallikrein-like activity in the conditioned medium of HUVEC.
HUVEC were cultured in 75-cm2 dishes with EBM for 8, 16, and 24 h. The
conditioned medium was dialyzed overnight against distilled water, then
lyophilized. The lyophilizates were dissolved in 0.5 ml of 0.1 M Tris–HCl,
pH 7.8, containing 10 Ag/ml of bovine serum albumin and 0.1 M NaCl, and
the kallikrein-like activity in samples was assayed using Pro-Phe-Arg-MCA
as a substrate, as described in the text. Enzyme activity was expressed as
nmol AMC/mg protein of HUVEC/h. Each point and vertical bar indicates
the meanFS.D. of three dishes.
Fig. 2. Western blots of human tissue kallikrein in the conditioned medium
of HUVEC. Kallikrein-like enzyme in the conditioned medium of HUVEC
was concentrated by an aprotinin–agarose column, then resolved by
Western blotting using rabbit anti-human tissue kallikrein antibodies, as
described in the text. Sample lane contains a kallikrein-like protein
corresponding to the amount obtained from the conditioned medium of two
75-cm2 dishes in 24-h cultures. The culture medium alone without HUVEC
was also applied to the aprotinin–agarose column, and the eluate was
resolved by the same procedures, as a blank. Human urinary kallikrein (40
ng/lane) was used as a positive standard. The numbers to the right of the
blot represent molecular mass standards in kDa.
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HUVEC and HAEC (Fig. 4), but no signals could be
detected corresponding to H-kininogen mRNA in these cells
(data not shown).
Fig. 3. Immunostaining of tissue kallikrein localized in HUVEC. The immunoreactive kallikrein was visualized with rabbit anti-human tissue kallikrein
antibodies followed by an immunoperoxidase staining procedure using biotinylated goat anti-rabbit IgG/peroxidase-labeled streptoavidin (A). Equally diluted
normal rabbit serum served as the negative control (B). Cells were counterstained with Mayer’s hematoxylin, and the immunostaining viewed at 400.
Fig. 4. Representative RT-PCR Southern blots of tissue kallikrein mRNA
and L-kininogen mRNA in HUVEC. RT-PCR (40 cycles) was carried out
using primers specific for human tissue kallikrein or human L-kininogen,
then Southern hybridization of amplified products using an oligonucleotide
probe for tissue kallikrein or human L-kininogen cDNA, respectively.
Tissue kallikrein mRNA (upper panel) was analyzed in HUVEC, human
coronary artery smooth muscle cells (HSMC) and HeLa cells, and
kininogen mRNA (lower panel) in HUVEC, HAEC, and HepG2 cells.
Each panel also shows RT-PCR Southern blots of GAPDH. Representative
blots of RNA samples from three different cultures of cells are shown.
Fig. 5. De novo synthesis of tissue kallikrein in HUVEC. HUVEC and
HAEC were metabolically labeled with [35S]methonine for 24 h, then the
conditioned medium was immunoprecipitated with rabbit anti-human tissue
kallikrein antibodies. The immunoprecipitates were resolved on SDS-
PAGE, then autoradiographed using a Fuji Film Bio Imaging Analyzer
BAS2000. In the lane of ‘competitor’, the immunoprecipitates from
radiolabeled HUVEC medium supplemented with 200-ng human urinary
kallikrein were resolved with similar procedures. The numbers to the right
of the blot represent molecular mass standards in kDa.
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3.4. Demonstration of de novo synthesis of tissue kallikrein
by endothelial cells
To confirm the de novo synthesis of tissue kallikrein by
HUVEC, we performed metabolic labeling of the HUVEC
or HAEC with [35S]methionine; subsequently, tissue kallik-
rein in the conditioned medium was immunoprecipitated
with rabbit anti-human tissue kallikrein antibodies. As
shown in Fig. 5, the immunoprecipitates from the condi-
tioned medium of either culture of human endothelial cells
consisted of two major radioactive proteins between the
molecular weights of 28 and 32 kDa. These two bands
disappeared after the excess addition of human urinary
kallikrein in the immunoprecipitation step. Since [125I]-
labeled human urinary kallikrein, as well as immunopreci-
pitates from conditioned medium of HeLa cells precultured
with [35S]methionine (data not shown), also exhibited two
bands with similar molecular sizes, these two proteins
released from endothelial cells appeared to be the active
forms of tissue kallikrein with heterogeneity in their carbo-
hydrate contents as reported previously [16].
3.5. Elevation of cGMP levels in HUVEC by lisinopril
To determine whether tissue kallikrein secretion from
HUVEC is involved in the generation of kinins which in
turn stimulates the NO/cGMP system, we examined the
effect of the angiotensin converting enzyme inhibitor, lisi-
nopril, on the cGMP levels in HUVEC in vitro (Fig. 6).
When HUVEC were incubated for 30 min in the presence of
1 AM lisinopril and IBMX, a phosphodiesterase inhibitor,
the cGMP levels in HUVEC were significantly elevated.
This elevation of the cGMP levels in HUVEC was com-
pletely inhibited by B2-receptor antagonist FR172357 (1
AM) or aprotinin (1 Ag/ml), while FR172357 or aprotinin
alone did not affect the cGMP levels (Fig. 6).
4. Discussion
Many studies have reported evidence that the vascular
wall is a source of kallikrein: Oza et al. [7] demonstrated
that rat vascular smooth muscle cells synthesized and
secreted tissue kallikrein, and Nolly et al. [8] also demon-
strated that the vascular tissues synthesize tissue kallikrein
using rat vascular rings and isolated perfused hindquarters.
Furthermore, Graf et al. [10] demonstrated that HUVEC, in
addition to endothelial cells from human pulmonary arteries,
contained a tissue kallikrein-like enzyme activity. The local
distribution of tissue kallikrein has been demonstrated by
immunostaining in endothelial and smooth muscle cells of
human blood vessels, and the site of tissue kallikrein syn-
thesis in blood vessels was also identified in these cells by in
situ hybridization histochemistry [11]. In addition to these
findings, the present study demonstrated that the condi-
tioned medium of HUVEC or HAEC contained tissue
kallikrein that had been de novo synthesized and secreted
by endothelial cells, and that the proteins could not be
distinguished from human urinary kallikrein in terms of the
molecular size and susceptibility to protease inhibitors.
Recently, Dedio et al. [12] reported the presence of tissue
kalikrein-like activity in lysates of HUVEC with a molec-
ular size of about 50 kDa. On the basis of findings that the
intracellular proteins having similar molecular sizes were
radiolabeled in HUVEC prelabeled with [35S]-cysteine/
methionine and that an anti-peptide antibody against the
activation site of prokallikrein did not detect traces of
prokallikrein in HUVEC lysates, it was suggested that most
of the de novo synthesized tissue kallikrein was stored
within the cells as an activated form, not as an inactive
prokallikrein form [12]. In contrast to their findings on the
tissue kallikrein-like protease in HUVEC, we presently
demonstrated the presence of an active form of tissue
kallikrein with a molecular size of about 30 kDa in the
conditioned medium of HUVEC: the tissue kallikrein-like
enzyme secreted by HUVEC exhibited the same mobility on
SDS-PAGE as that of human urinary kallikrein whose
molecular weight was reported to be about 30 kDa [16].
Furthermore, the radiolabeled tissue kallikrein, synthesized
de novo by HUVEC and HAEC, consisted of two major
bands on SDS-PAGE which exhibited exactly the same
profile as that of [125I]-labeled human urinary kallikrein,
suggesting that the enzyme from HUVEC had similar
heterogeneity in carbohydrate content as urinary kallikrein.
However, it is unknown why the molecular sizes of the
Fig. 6. Effect of lisinopril on cGMP levels in HUVEC. HUVEC in 4-cm2
dishes were washed by HBSS, then incubated in HBSS containing 0.1 mM
IBMX at 37 jC for 15 min. Cells were incubated for further 30 min with or
without lisinopril (1 AM), FR172357 (1 AM), or aprotinin (10 Ag/ml) at 37
jC. cGMP was extracted from cells with 0.1 N HCl (0.5 ml) and measured
from neutralized supernatant by radioimmunoassay. Bars indicate
meansFS.D. of four to eight dishes. Significantly different from untreated
control (*P<0.05).
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active form of tissue kallikrein secreted from HUVEC were
different from those stored within HUVEC as reported by
Dedio et al. [12].
When the conditioned medium of HUVEC was concen-
trated and incubated with a partially purified bovine kini-
nogen, a kinin-like contractile activity on the rat uterus
appeared during the course of incubation (data not shown).
The kinin-like contractile activity was not generated in the
presence of aprotinin during the incubation, suggesting that
tissue kallikrein derived from HUVEC is responsible for
kinin release from bovine kininogen. Thus, it is likely that
the tissue kallikrein released from HUVEC has a kinin-
generating activity. Therefore, it is hypothesized that an
active form of tissue kallikrein released from HUVEC
generated kinins, which in turn stimulated the B2-receptor
on HUVEC. In fact, it was reported that the angiotensin
converting enzyme inhibitor, ramiprilat, increases cGMP
levels in HUVEC in vitro, and that the effect is inhibited
by the B2-antagonist, Hoe-140, and the NO synthase
inhibitor, NG-nitro-L-arginine, suggesting that HUVEC gen-
erates kinins to enhance the NO/cGMP system [17]. To test
the contribution of tissue kallikrein on the kinin generation
by HUVEC, the cGMP levels in HUVEC were determined
after the addition of the angiotensin converting enzyme
inhibitor, lisinopril, in the presence or absence of aprotinin.
We found that the cGMP levels in HUVEC were signifi-
cantly increased by lisinopril, and that the addition of
aprotinin or FR172357 completely inhibited the effect of
lisinopril. These findings suggest that HUVEC continuously
release an active form of tissue kallikrein which is respon-
sible for the generation of kinins on HUVEC, and that
lisinopril enhances the action of kinins on the B2-receptor of
HUVEC by blocking their degradation.
In contrast to kallikrein, little evidence has been reported
on the kininogen in vascular tissues. Although it was
reported that rat vascular smooth muscle cells release a
kininogen-like protein that liberates a kinin by trypsin
digestion [7], our previous studies demonstrated that rat
vascular smooth muscle cells express T-kininogen but not
H-and L-kininogens [18]. Figueroa et al. [19] demonstrated
that the immunoreactive H-kininogen localizes in the endo-
thelial cells of human large vessels. It is well documented
that high affinity binding sites for H- and L-kininogens are
present on endothelial cells [20,21], and that kinin is
generated from endothelial-bound H-kininogen by plasma
kallikrein [22]. As shown in the present study, the incuba-
tion of HUVEC with lisinopril increased cGMP levels in
vitro, probably by the action of kinins, but this does not
clarify where kininogen comes from. There is a possibility
that the H- and L-kininogens in FCS bound to the binding
sites of the cell surface during subcultures with 10% FCS
and remained there after washing. Another possibility is that
kininogens are synthesized and released from HUVEC. In
fact, we found that both HUVEC and HAEC express L-
kininogen mRNA. However, since the H- and L-kininogens
derived from the liver are abundant in the circulation, it is
likely that the local generation of kinins on the endothelium
in situ depends on the release of the active form of tissue
kallikrein from endothelial cells. Recently, Bergaya et al.
[23] reported that an exogenous infusion of kininogen in the
carotid arteries caused a dilation of arteries in wild-type
mice, but not in tissue kallikrein-knockout mice. Moreover,
they demonstrated that the flow-dependent vasodilation
response was impaired in tissue kallikrein-knockout mice
[23], suggesting a physiological contribution of the vascular
kallikrein–kinin system in the maintenance of circulation
homeostasis. Thus, it will be important to elucidate the
mechanisms by which the synthesis and release of tissue
kallikrein from the endothelium are controlled for under-
standing not only the pharmacological actions of angioten-
sin converting enzyme inhibitors but also the pathophysio-
logical role of kinins in cardiovascular tissues.
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